At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 260 enrolled
Drug / intervention
pemetrexed +2 moredrug
Likely dose
pemetrexed 500 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized Phase 3 Study Comparing Pemetrexed-Carboplatin With Docetaxel-Carboplatin as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
In Brief
A Phase 3 clinical trial evaluating pemetrexed, docetaxel, and 1 other intervention for Non-Small Cell Lung Cancer. Completed, enrolled 260 participants across 20 sites in 6 countries.
Detailed Summary
The purpose of this study is to compare the combination of pemetrexed and carboplatin with the combination of docetaxel and carboplatin in terms of survival without Grade 3 or 4 toxicity in previously untreated patients with locally advanced or metastatic non-small cell lung cancer (NSCLC).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-Small Cell Lung Cancer
CountriesAustralia, Brazil, China, Mexico, South Korea, Taiwan
Collaborators--
Timeline
Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 2007
Enrollment StartOct 2007
Primary CompletionJul 2010
TodayJul 2026
First PostedAug 24, 2007
Enrollment StartOct 1, 2007
Primary CompletionJul 1, 2010
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 18.9 years ago
Interventions
pemetrexeddrug
500 mg/m\^2, IV, q 21 days x 6 cycles maximum
docetaxeldrug
75 mg/m\^2, IV, q 21 days x 6 cycles maximum
carboplatindrug
AUC 5 mg\*min/mL, IV, q 21 days x 6 cycles maximum